Sarepta Therapeutics Inc
Change company Symbol lookup
Select an option...
SRPT Sarepta Therapeutics Inc
STLRU Stellar Acquisition III Inc
T AT&T Inc
KMX Carmax Inc
BAC Bank of America Corp
STDAY Stada Arzneimittel AG
PSBP Provident State Bank Inc
AJG Arthur J Gallagher & Co
ALL Allstate Corp
PFK Prudential Financial Inc
Go

Health Care : Biotechnology | Small Cap GrowthCompany profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Closing Price
$36.26
Day's Change
1.54 (4.44%)
Bid
--
Ask
--
B/A Size
--
Day's High
39.34
Day's Low
35.20
Volume
(Heavy Day)
Volume:
9,469,270
10-day average volume:
2,947,918
9,469,270
  • Prev Close
    34.72
  • Today's Open
    38.00
  • Day's Range
    35.20-39.34
  • Avg Vol (10-day)
    2.9M
  • Last (time)
    4:00p ET 04/28/17
  • Last (size)
    70
  • 52-Wk Range
    13.25 - 63.73
    LowHigh
  • (04/28/16 - 09/28/16)
    173.66%
  • 100.3%
  • Market Cap
    2.0B
  • Shares Outstanding
    54.8M
  • -5.45
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.4
  • 71.03
  • (% of float 04/15/17)
    21.23

Latest News

April 27, 2017
4:01 pm ET
Globe Newswire
April 18, 2017
11:20 am ET
PR Newswire
April 17, 2017
8:30 am ET
Globe Newswire
April 07, 2017
7:00 am ET
PR Newswire
April 05, 2017
5:00 pm ET
Globe Newswire
April 03, 2017
8:30 am ET
Globe Newswire
March 31, 2017
6:30 pm ET
Globe Newswire
March 30, 2017
8:30 am ET
Globe Newswire
March 28, 2017
11:42 am ET
Globe Newswire
March 17, 2017
8:30 am ET
Globe Newswire
March 02, 2017
6:00 pm ET
Globe Newswire
February 28, 2017
6:46 pm ET
BusinessWire
4:03 pm ET
BusinessWire
10:43 am ET
PR Newswire
February 21, 2017
7:01 am ET
BusinessWire
February 15, 2017
8:31 am ET
BusinessWire
February 13, 2017
4:12 pm ET
MarketWatch
4:02 pm ET
MarketWatch
February 10, 2017
7:10 am ET
PR Newswire
February 09, 2017
3:51 pm ET
MarketWatch
January 31, 2017
5:15 pm ET
BusinessWire
January 19, 2017
9:08 am ET
MarketWatch
December 22, 2016
8:21 am ET
MarketWatch
November 17, 2016
9:28 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2017 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , , and

Copyright © 2017. All rights reserved.